Jump to content

Olopatadine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Citation bot (talk | contribs)
Bots
5,025,215 edits
Altered template type. Add: vauthors, pmc, doi, pages, issue, volume, journal, title, date, pmid. Removed URL that duplicated identifier. Changed bare reference to CS1/2. | Use this bot. Report bugs. | Suggested by Maxim Masiutin | #UCB_webform
Rescuing 6 sources and tagging 0 as dead.) #IABot (v2.0.9.5
Line 100: Line 100:


<!-- Definition and medical uses -->
<!-- Definition and medical uses -->
'''Olopatadine''', sold under the brand name '''Patanol''' among others, is an antihistamine medication used to decrease the symptoms of [[allergic conjunctivitis]] and [[allergic rhinitis]] (hay fever).<ref name=AHFS2019>{{cite web |title=Olopatadine Hydrochloride Monograph for Professionals |url=https://www.drugs.com/monograph/olopatadine-hydrochloride.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=26 March 2019}}</ref> It is used as [[Ophthalmic drug administration|eye drops]] or as a [[Nasal administration|nasal spray]].<ref name=AHFS2019/> The eye drops generally result in an improvement within half an hour.<ref name=AHFS2019/>
'''Olopatadine''', sold under the brand name '''Patanol''' among others, is an antihistamine medication used to decrease the symptoms of [[allergic conjunctivitis]] and [[allergic rhinitis]] (hay fever).<ref name=AHFS2019>{{cite web |title=Olopatadine Hydrochloride Monograph for Professionals |url=https://www.drugs.com/monograph/olopatadine-hydrochloride.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=26 March 2019 |archive-date=27 March 2019 |archive-url=https://web.archive.org/web/20190327091820/https://www.drugs.com/monograph/olopatadine-hydrochloride.html |url-status=live }}</ref> It is used as [[Ophthalmic drug administration|eye drops]] or as a [[Nasal administration|nasal spray]].<ref name=AHFS2019/> The eye drops generally result in an improvement within half an hour.<ref name=AHFS2019/>


<!-- Side effects and mechanisms -->
<!-- Side effects and mechanisms -->
Common side effects include headache, sore throat, eye discomfort, or changes in perception of taste.<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=1126|edition=76}}</ref><ref name=AHFS2019/> More significant side effects may include sleepiness.<ref name=AHFS2019/> It is unclear if use during [[pregnancy]] or [[breastfeeding]] is safe.<ref>{{cite web |title=Olopatadine ophthalmic Use During Pregnancy |url=https://www.drugs.com/pregnancy/olopatadine-ophthalmic.html |website=Drugs.com |access-date=26 March 2019 }}</ref> It is an [[antihistamine]] and [[mast cell stabilizer]].<ref name=Cas2015>{{cite journal | vauthors = Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A | title = Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis | journal = The Cochrane Database of Systematic Reviews | volume = 2015 | issue = 6 | pages = CD009566 | date = June 2015 | pmid = 26028608 | doi = 10.1002/14651858.CD009566.pub2 | pmc = 10616535 | url = http://aura.abdn.ac.uk/bitstream/2164/6048/1/Castillo_et_al_2015_The_Cochrane_Library.pdf | hdl = 2164/6048 | hdl-access = free }}</ref><ref name=AHFS2019/>
Common side effects include headache, sore throat, eye discomfort, or changes in perception of taste.<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=1126|edition=76}}</ref><ref name=AHFS2019/> More significant side effects may include sleepiness.<ref name=AHFS2019/> It is unclear if use during [[pregnancy]] or [[breastfeeding]] is safe.<ref>{{cite web |title=Olopatadine ophthalmic Use During Pregnancy |url=https://www.drugs.com/pregnancy/olopatadine-ophthalmic.html |website=Drugs.com |access-date=26 March 2019 |archive-date=26 March 2019 |archive-url=https://web.archive.org/web/20190326155258/https://www.drugs.com/pregnancy/olopatadine-ophthalmic.html |url-status=live }}</ref> It is an [[antihistamine]] and [[mast cell stabilizer]].<ref name=Cas2015>{{cite journal | vauthors = Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A | title = Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis | journal = The Cochrane Database of Systematic Reviews | volume = 2015 | issue = 6 | pages = CD009566 | date = June 2015 | pmid = 26028608 | doi = 10.1002/14651858.CD009566.pub2 | pmc = 10616535 | url = http://aura.abdn.ac.uk/bitstream/2164/6048/1/Castillo_et_al_2015_The_Cochrane_Library.pdf | hdl = 2164/6048 | hdl-access = free | access-date = 24 September 2019 | archive-date = 28 August 2021 | archive-url = https://web.archive.org/web/20210828051138/http://aura.abdn.ac.uk/bitstream/handle/2164/6048/Castillo_et_al_2015_The_Cochrane_Library.pdf;jsessionid=D8DC7729A66970DF95B91197B5CFDB6E?sequence=1 | url-status = live }}</ref><ref name=AHFS2019/>


<!-- Society and culture -->
<!-- Society and culture -->
Olopatadine was patented in 1986 and came into medical use in 1997.<ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=549 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA549 }}</ref> It is available as a [[generic medication]].<ref name=AHFS2019/> In 2021, it was the 263rd most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Olopatadine - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Olopatadine | access-date = 14 January 2024}}</ref>
Olopatadine was patented in 1986 and came into medical use in 1997.<ref name=Fis2006>{{cite book |vauthors=Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=549 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA549 |access-date=20 September 2020 |archive-date=10 January 2023 |archive-url=https://web.archive.org/web/20230110005657/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA549 |url-status=live }}</ref> It is available as a [[generic medication]].<ref name=AHFS2019/> In 2021, it was the 263rd most commonly prescribed medication in the United States, with more than 1{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Olopatadine - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Olopatadine | access-date = 14 January 2024 | archive-date = 8 July 2020 | archive-url = https://web.archive.org/web/20200708073651/https://clincalc.com/DrugStats/Drugs/Olopatadine | url-status = live }}</ref>


==Medical uses==
==Medical uses==
Line 133: Line 133:
== Society and culture ==
== Society and culture ==
=== Brand names ===
=== Brand names ===
[[File:Pallada Olopatadinum Olopatadine.jpg|thumb|right|A package of generic formulation of olopatadine eye drops sold under the brand name Pallada]]Brand names include Pallada, Pazeo, Pataday, Patanol S, Patanol, Opatanol, Olopat, Patanase.<ref>[https://www.drugs.com/newdrugs/alcon-s-patanase-nasal-approved-fda-nasal-allergy-symptoms-942.html Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms]</ref> It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by [[Kyowa Hakko Kogyo]].<ref name=KYOWA08>{{cite web | author = Kyowa Hakko Kogyo Co., Ltd. | year = 2007 | url = http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF | title = Allelock Tablets 2.5 & Allelock Tablets 5 (English) | access-date = 10 August 2008 | archive-url = https://web.archive.org/web/20110722114455/http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF | archive-date = 22 July 2011 | url-status = dead }}</ref>
[[File:Pallada Olopatadinum Olopatadine.jpg|thumb|right|A package of generic formulation of olopatadine eye drops sold under the brand name Pallada]]Brand names include Pallada, Pazeo, Pataday, Patanol S, Patanol, Opatanol, Olopat, Patanase.<ref>{{Cite web |url=https://www.drugs.com/newdrugs/alcon-s-patanase-nasal-approved-fda-nasal-allergy-symptoms-942.html |title=Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms |access-date=23 January 2018 |archive-date=17 April 2009 |archive-url=https://web.archive.org/web/20090417080723/http://www.drugs.com/newdrugs/alcon-s-patanase-nasal-approved-fda-nasal-allergy-symptoms-942.html |url-status=live }}</ref> It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by [[Kyowa Hakko Kogyo]].<ref name=KYOWA08>{{cite web | author = Kyowa Hakko Kogyo Co., Ltd. | year = 2007 | url = http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF | title = Allelock Tablets 2.5 & Allelock Tablets 5 (English) | access-date = 10 August 2008 | archive-url = https://web.archive.org/web/20110722114455/http://www.e-search.ne.jp/~jpr/PDF/KYOWA08.PDF | archive-date = 22 July 2011 | url-status = dead }}</ref>


== References ==
== References ==

Revision as of 11:52, 13 July 2024

Olopatadine
Clinical data
Trade namesPatanol, Pataday, Opatanol
AHFS/Drugs.comMonograph
MedlinePlusa602025
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Eye drops, nasal spray
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only / OTC[1]
  • EU: Rx-only
Pharmacokinetic data
Elimination half-life3 hours
Identifiers
  • {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-
    dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23NO3
Molar mass337.419 g·mol−1
3D model (JSmol)
  • O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc3
  • InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- checkY
  • Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Olopatadine, sold under the brand name Patanol among others, is an antihistamine medication used to decrease the symptoms of allergic conjunctivitis and allergic rhinitis (hay fever).[2] It is used as eye drops or as a nasal spray.[2] The eye drops generally result in an improvement within half an hour.[2]

Common side effects include headache, sore throat, eye discomfort, or changes in perception of taste.[3][2] More significant side effects may include sleepiness.[2] It is unclear if use during pregnancy or breastfeeding is safe.[4] It is an antihistamine and mast cell stabilizer.[5][2]

Olopatadine was patented in 1986 and came into medical use in 1997.[6] It is available as a generic medication.[2] In 2021, it was the 263rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]

Medical uses

Olopatadine is used in eye drops to treat allergic conjuctivites—a condition manifested as itchy, red, watery eyes. Olopatadine aims to be a better alternative for eye drops containing corticosteroids. The use of olopatadine aims to reduce side effects produced by corticosteroids, which include, among others, elevated intraocular pressure—a risk factor for glaucoma—and increased risk of infection.[9]

Side effects

Some known side effects include headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, taste perversion, and vomiting.

Chemistry

Synthesis

Olopatadine synthesis:[10]

Pharmacology

Pharmacodynamics

Olopatadine acts as a selective antagonist of the histamine H1 receptor, thus stabilizing mast cells and inhibiting histamine release.

History

Olopatadine was patented in 1986 by Kyowa Hakko Kogyo and came into medical use in 1997.[6]

In the United States, Pataday Twice Daily Relief was first approved by the FDA in 1996, under the name Patanol as a prescription drug and was indicated for the treatment of the signs and symptoms of allergic conjunctivitis (referring to ocular redness and itching due to allergies).[1] Pataday – now Pataday Once Daily Relief – was first approved by the FDA in 2004, as a prescription drug and was indicated for the treatment of ocular itching associated with allergic conjunctivitis.[1] These drugs are mast cell stabilizers, which work by preventing the release of histamine and therefore prevent or control allergic disorders.[1]

In February 2020, Pataday Twice Daily Relief and Pataday Once Daily Relief were switched to be over-the-counter drugs in the United States when the FDA granted the approvals of the nonprescription products to Alcon.[1]

Society and culture

Brand names

A package of generic formulation of olopatadine eye drops sold under the brand name Pallada

Brand names include Pallada, Pazeo, Pataday, Patanol S, Patanol, Opatanol, Olopat, Patanase.[11] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.[12]

References

  1. ^ a b c d e "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process". U.S. Food and Drug Administration (FDA). 14 February 2020. Archived from the original on 15 February 2020. Retrieved 14 February 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ a b c d e f g "Olopatadine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 26 March 2019.
  3. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1126. ISBN 9780857113382.
  4. ^ "Olopatadine ophthalmic Use During Pregnancy". Drugs.com. Archived from the original on 26 March 2019. Retrieved 26 March 2019.
  5. ^ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (June 2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis" (PDF). The Cochrane Database of Systematic Reviews. 2015 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. hdl:2164/6048. PMC 10616535. PMID 26028608. Archived from the original on 28 August 2021. Retrieved 24 September 2019.
  6. ^ a b Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 549. ISBN 9783527607495. Archived from the original on 10 January 2023. Retrieved 20 September 2020.
  7. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  8. ^ "Olopatadine - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 14 January 2024.
  9. ^ Zi Y, Deng Y, Ji M, Qin Y, Nong L, Liu Z, et al. (2020). "The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review". Medicine. 99 (7): e18618. doi:10.1097/MD.0000000000018618. PMC 7035116. PMID 32049778.
  10. ^ Ueno K, Kubo S, Tagawa H, Yoshioka T, Tsukada W (July 1976). "6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity". Journal of Medicinal Chemistry. 19 (7): 941–6. doi:10.1021/jm00229a017. PMID 940112.
  11. ^ "Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms". Archived from the original on 17 April 2009. Retrieved 23 January 2018.
  12. ^ Kyowa Hakko Kogyo Co., Ltd. (2007). "Allelock Tablets 2.5 & Allelock Tablets 5 (English)" (PDF). Archived from the original (PDF) on 22 July 2011. Retrieved 10 August 2008.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Olopatadine&oldid=1234256667"